Rational therapy for recurrent infections of the lower urinary tract. The results of a prospective observational program to assess the effectiveness and safety of Ceforal®, Solutab® and Uro-Vaksom® in patients with recurrent uncomplicated lower urinary tract infections (FLORA)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Remaining generally unchanged, urinary tract infection (UTI) treatment protocols require continuing monitoring due to growing antibiotic resistance and lowered immune status of the majority of patients. The article presents the results of a prospective observational program carried out the Russian Federation in to assess the effectiveness and safety of Ceforal®, Solutab® and Uro-Vaksom® in patients with recurrent uncomplicated lower urinary tract infections (FLORA). The results of the program suggest that Ceforal® Solutab® and Uro- Vaksom® administered as a part of routine clinical practice contribute to a significant reduction in the number of UTI recurrences and have a good safety profile. These findings support recommendation to use this treatment protocol in patients with recurrent UTI, taking into account individual and epidemiological features.

About the authors

O B Loran

Russian Medical Academy of Postgraduate Education of Minzdrav of Russia

Russian Medical Academy of Postgraduate Education of Minzdrav of Russia

M I Kogan

Rostov State Medical University

Rostov State Medical University

L A Sinjakova

Russian Medical Academy of Postgraduate Education of Minzdrav of Russia

Russian Medical Academy of Postgraduate Education of Minzdrav of Russia

A G Ivanov

Rostov State Medical University

Rostov State Medical University

A Z Vinarov

Sechenov First MoscowState Medical University

Sechenov First MoscowState Medical University

L G Spivak

Sechenov First MoscowState Medical University

Sechenov First MoscowState Medical University

K L Lokshin

Sechenov First MoscowState Medical University

Sechenov First MoscowState Medical University

A V Zajcev

Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov

Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov

I L Korsunskaja

Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov

Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov

F P Kapsargin

Krasnoyarsk State Medical University n. a. V.F. Voyno-Yasenetsky

Krasnoyarsk State Medical University n. a. V.F. Voyno-Yasenetsky

E Ju Hlebnova

Krasnoyarsk State Medical University n. a. V.F. Voyno-Yasenetsky

Krasnoyarsk State Medical University n. a. V.F. Voyno-Yasenetsky

References

  1. Рафальский В.В., Ходневич Л.В. Влияние резистентности возбудителей инфекций мочевыводящих путей на исходы антибактериальной терапии. Урология. 2008;4:3-9.
  2. Talan D.A. Urinary tract infections. N. Engl. J. Med. 2003;349(17):612-618.
  3. Hooton T., Besser R., Foxman B., Fritsche T., Nicole L. Acute Uncomplicated Cystitis in Era of Increasing Antibiotic Resistance: A Proposed Approach. Clin. Infect. Dis. 2004; 39(1):75-80.
  4. Naber K.G., Bergman B, Bjerklund-Johansen T.E., Botto H, Label B, Jimines Cruz F, Selvaggi F.P. Guidelaines on urinary and male genital infections. European Association of Urology, 2001.
  5. Лоран О.Б., Зайцев А.В., Годунов Б.Н. Современные аспекты диагностики и лечения хронического цистита у женщин. Урология и нефрология. 1997;6:7-14.
  6. Палагин И.С., Сухорукова М.В., Дехнич А.В., Эйдельштейн М.В., Шевелев А.Н., Гринев А.В., Перепанова Т.С., Козлов Р.С., исследовательская группа «ДАРМИС». Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России. Клин. микробиол. антимикроб. химиотер. 2012;14(4):280-302. 7.
  7. Антимикробная терапия и профилактика инфекций почек, мочевыводящих путей и мужских половых органов. Российские национальные рекомендации. Под ред. Черепановой Т.С., Козлова Р.С., Руднова В.А., Синяковой Л.А. М., 2014. 63 с.
  8. Лоран О.Б. Синякова Л.А. Воспалительные заболевания органов мочевой системы. Актуальные вопросы. Пособие для врачей. М.: МИА, 2014. 84 с. 9.
  9. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Российские практические рекомендации. Под ред. Яковлева С.В., Сидоренко С.В., Рафальского В.В., Спичак Т.В. М.: Престо, 2014. 121 с. 10.
  10. РафальскийВ.В., Белокрысенко С.С., МалевИ.В., ДеревицкийА.В., Галкин В.В., Остроумова М.В., Ляхова О.А. Чувствительность возбудителей инфекций мочевыводящих путей, выделенных в Российской Федерации, к пероральному цефалоспорину III поколения цефиксиму. Лечащий врач. 2008;8:27-29. 11.
  11. Grabe M et al. European Association of Urology Guidelines on Urological Infections 2014. www.uroweb.org <http://www.uroweb.org>.
  12. Галкин В.В., Довгань Е.В., Козлов С.Н., Рафальский В.В. Цефиксим в сравнении с ципрофлоксацином при остром неосложненном цистите: клинико-экономическое исследование. КМАХ. 2012;1:50-66.
  13. Naber K.G., Cho Y.H., Matsumoto T, Schaeffer A.J. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int. J. Antimicrob. Agents. 2009;33(2):111-119.
  14. Bauer H.W., Rahlfs V.W., Lauener P.A., Blessmann G.S. Prevention of recurrent tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int. J. Antimicrob. Agents. 2002;19:451-456.
  15. Tammen H., Frey Ch. Treatment of recurrent uiinay tract infections with Uro-Vaxom®. Open multicenter study with 521 patients. Urologe B. 1988;28:294-296. 16.
  16. BaertschiR., Balmer J.A., Eduah S.B., Liechti A., Lurie D., Schams H. Bacterial extract for the prevention of recurrent urinary tract infections in pregnant women: a pilot study. Int. J. Immunother. 2003;19:25-31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media